Sydney-based Pharmaxis(ASX:PXS) has announced it is progressing the development of an oral anti‐fibrotic Lysyl Oxidase (LOX) inhibitor for the treatment of myelofibrosis and pancreatic cancer. …
Latest Video
New Stories
-
Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial
November 13, 2025 - - Australian Biotech -
Australia joins global WHO task force to tackle antimicrobial resistance
November 13, 2025 - -
New post-market review workplan focuses on real-world data and patient outcomes
November 13, 2025 - - Latest News -
Government adds new first-line treatment to the PBS for deadly blood cancer
November 13, 2025 - -
RAGE Biotech raises $29 million and appoints new leadership to advance precision RNA therapeutics
November 13, 2025 - - Latest News -
Nanosonics names new North American president ahead of CORIS launch
November 13, 2025 - - Australian Biotech -
Australians open to AI in healthcare, but prefer doctors to be in control
November 13, 2025 - - Latest News